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Introduction {#sec1}
============

Healthy cartilage of joints is stably maintained, but damaged cartilage is not spontaneously repaired in large animals and humans, leading to severe wear of the whole joint cartilage and consequent osteoarthritis ([@bib6]). The current cell-based and tissue engineering-based therapies, which use mesenchymal stromal cells (MSCs) and dedifferentiated articular chondrocytes, are far from ideal on a number of fronts ([@bib46]). One of the major challenges is to prevent the (re)generated cartilage from entering an endochondral ossification program after transplantation ([@bib45]). Such a program results in hypertrophic differentiation, mineralization/calcification, and the death of chondrocytes, followed by angiogenesis and bone growth, as in the growth plate. Similar changes are also observed during osteoarthritic cartilage degeneration ([@bib40], [@bib51]).

Chondrogenesis is most active during prenatal and early postnatal stages. Surface injury introduced into fetal joint cartilage *in utero* is repaired spontaneously and completely, even in a large animal model ([@bib36]), suggesting that embryonic epiphyseal chondrocytes may possess the capacity to regenerate joint articular cartilage without being committed to endochondral ossification. For humans, pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced PSCs (iPSCs), are the only practical source of embryonic cells. Chondroprogenitors have already been developed from mouse (m) and human (h) PSCs and characterized *in vitro* and *in vivo* ([@bib35], [@bib33]). Interestingly, we and others have recently shown that tissue-engineered cartilage produced from mesodermal progeny of hPSCs under scaffold-free conditions *in vitro* (i.e., cartilage pellet) tended to stay in an unmineralized state when transplanted at ectopic sites in immunocompromised rodents ([@bib12], [@bib50], [@bib56]), as did a piece of articular cartilage ([Figure S1](#mmc1){ref-type="supplementary-material"}A). This tendency is preserved even when cartilage is formed in the presence of bone morphogenetic protein (BMP) ([@bib50], [@bib56]), which enhances chondrogenesis but also hypertrophic differentiation of chondrocytes ([@bib31], [@bib48]). However, when such mesodermal progeny were expanded and maintained in culture, the resulting cartilage pellets matured readily and became fully mineralized after transplantation ([Figure S1](#mmc1){ref-type="supplementary-material"}B). So too did the chondrogenic ectomesenchymal cells developed by an expansion culture of neural crest-like progeny of hPSCs ([@bib50]). Thus, regardless of the developmental origin, expanded chondroprogenitors may have a tendency to give rise to growth-plate-like, endochondral ossification-ready chondrocytes. However, expansion of chondrogenic cells such as MSCs is often needed to gain sufficient cells for treatment.

One way to avoid endochondral ossification in chondrocytes developed from expanded chondroprogenitors is to mimic the parathyroid hormone-related peptide (PTHrP) signaling that keeps growth-plate chondrocytes in the proliferative state and suppresses their hypertrophic differentiation ([@bib1], [@bib24]). During embryonic skeletogenesis, early epiphyseal chondrocytes express PTHrP and low levels of its receptor. Later, the Indian hedgehog (IHH)-PTHrP negative feedback loop controls the speed of hypertrophic differentiation and terminal maturation of growth-plate chondrocytes ([@bib27], [@bib52]). Increased cAMP is responsible for such effects of PTHrP ([@bib42]). The rise in cAMP leads to activation of Sox9, the master regulator of (immature) chondrocytes, through the action of cAMP-dependent protein kinase (PKA) ([@bib21], [@bib20]), which also leads to inhibition of Mef2c action and suppression of chondrocyte hypertrophic differentiation ([@bib26]). PTHrP causes a decrease in the mRNA level of *Runx2*, the master regulator for mineralization (bone formation) and hypertrophic differentiation of chondrocytes ([@bib29]), and stimulates degradation of Runx2 protein ([@bib58]), which delays chondrocyte hypertrophic differentiation ([@bib17]). Furthermore, *Pthrp* mutant mice show mineralization of nasal cartilage ([@bib10]), suggesting that nasal cartilage is maintained permanently in an unmineralized state via PTHrP signaling.

Here, we report that treatment with the small-molecule activator of adenylyl cyclase forskolin, which directly increases intracellular cAMP levels during chondrogenesis from hPSC-derived ectomesenchymal cells, suppresses hypertrophic differentiation and terminal maturation of developed chondrocytes potentially via maintaining their proliferative state. Forskolin also increases their capacity to produce hyaline cartilage matrix. Furthermore, forskolin treatment prevents cartilage pellets to varying degrees from becoming mineralized bony tissues when transplanted at an ectopic site in immunocompromised mice. Thus, the implementation of cAMP signaling seems to be an effective means of generating a long-lasting, endochondral ossification-resistant cartilage construct.

Results {#sec2}
=======

Forskolin Selectively Suppresses Type X Collagen Gene Expression in Hyaline-like Cartilage Pellets Induced with BMP4 from hPSC-Derived Ectomesenchymal Cells {#sec2.1}
------------------------------------------------------------------------------------------------------------------------------------------------------------

We used ectomesenchymal cells ([Figure 1](#fig1){ref-type="fig"}A) as a model hPSC-derived chondroprogenitor that forms large hyaline-like cartilage (i.e., type I collagen \[COL1\]^lo^, type II collagen \[COL2\]^+^) pellets in the presence of BMP ([Figures 1](#fig1){ref-type="fig"}B and 1E) ([@bib49]) and expresses type X collagen (COL10) mRNA (*COL10A1*), a marker of hypertrophic chondrocytes ([Figures 1](#fig1){ref-type="fig"}C and 1D) ([@bib50]) to screen for signaling modifiers that counteract the effect of BMP on hypertrophic differentiation of chondrocytes without disturbing its effect on hyaline chondrogenesis *in vitro*. We aimed to manipulate signaling mechanisms of canonical WNT (stabilizing β-catenin), PTHrP (increasing cAMP), and natriuretic peptide (NP, increasing cGMP). WNT and NP promote, and PTHrP antagonizes, hypertrophic differentiation of chondrocytes in the growth plate ([@bib35]).Figure 1Suppression of Hypertrophic Chondrocyte Gene Expression during Chondrogenesis from hESC-derived Ectomesenchymal Cells(A) Graphical representation of the experimental procedure. CDM, chemically defined medium; F, FGF2; Sb, SB431542; PT, PDGF + TGF-β; PTB, PT + BMP4; PTG, PT + GDF5; PT7, PT + BMP7.(B) BMP4 suppression of COL1 gene (*COL1A1*) expression during chondrogenesis. Mean relative expression levels from n = 5--9 (PTB) and n = 6 (PT) are shown with SEM as thin vertical lines and p value.(C) PTHrP suppression of *COL10A1* expression without affecting *COL2A1* expression. Mean value from n = 4 with SEM and p value. Right: Fold changes in expression by PTHrP treatment. Mean value of the "expression in PTHrP-treated pellets divided by that in untreated pellets" with SEM and p value.(D) Time-dependent changes in gene expression during chondrogenesis under PTB with (brown) or without (blue) forskolin (Fk) treatment (n = 2). Thin vertical line, SD.(E) Translucent cartilage pellet formation from H9 hESC-derived ectomesenchymal cells under PTB with or without Fk.(F) Histological and immunofluorescence staining of the cartilage pellet formed as in (E). Representative results of n = 3. TB, toluidine blue. The yellow arrow indicates the COL1^+^ area.(G) Composition of SOX9^+^ chondrocytes within the cartilage pellets formed under PTBFk from SOX9-GFP hiPSC-derived ectomesenchymal cells (left), analyzed by fluorescence-activated cell sorting (FACS). Those derived from H9 hESCs were used for the non-GFP control (right). Representative results of n = 8. Gene expression data are provided in [Figure S3](#mmc1){ref-type="supplementary-material"}C.

We first tested the effect of PTHrP directly ([Figure 1](#fig1){ref-type="fig"}C). Addition of PTHrP(1--34) peptide enhanced the growth of cartilage pellets and suppressed *COL10A1* expression without affecting COL2 mRNA (*COL2A1*) levels during chondrogenesis in the standard medium (PTB), which includes platelet-derived growth factor (PDGF), transforming growth factor (TGF) β3, and BMP4 ([@bib49], [@bib50]). During chondrogenesis, *COL2A1* expression was stimulated by TGF-β added from day 6 until the levels plateaued around days 20--30, whereas *COL10A1* expression became detectable after BMP4 treatment initiated on day 10 ([Figure 1](#fig1){ref-type="fig"}D). Accordingly, to restrict its effect on the BMP-promoted chondrocyte hypertrophic differentiation, we added PTHrP on days 11--12, when *COL2A1*^+^*COL10A1*^--^ immature chondrocytes were being made and BMP signal had just begun.

We further investigated small molecules known to directly elevate cAMP (forskolin), to inhibit canonical WNT signaling (iCRT14 and KY02111), to inhibit all WNT signaling (Verapamil and Wnt-C59), or to inhibit cGMP signaling (KT5824) ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2C). Initial screening demonstrated that forskolin strongly suppressed ([Figure S2](#mmc1){ref-type="supplementary-material"}A), and Wnt-C59 weakly suppressed ([Figure S2](#mmc1){ref-type="supplementary-material"}C), the expression of *COL10A1*, without significantly affecting *COL2A1* expression and growth of the cartilage pellet. Other agents failed to show a significant effect on *COL10A1* expression and were somewhat inhibitory to the growth of cartilage pellets.

Therefore, we focused on cAMP signaling activated by forskolin for further analysis. Forskolin added at 20--30 μM ([Figure S2](#mmc1){ref-type="supplementary-material"}D) during chondrogenesis under PTB reproducibly decreased and delayed the expression of *COL10A1* and to a lesser degree *RUNX2* (one of the critical *COL10A1* transcription factors), without affecting the level and kinetics of expression of the chondrocyte genes *COL2A1* and *SOX9* (the major *COL2A1* transcription factor) ([Figure 1](#fig1){ref-type="fig"}D). Immunohistological analysis showed that uniform metachromatic staining by toluidine blue (TB; i.e., uniform sulfated glycosaminoglycan \[sGAG\] accumulation) overlapped with COL2 immunostaining within the cartilage pellet but that COL1 was only detectable in the layer of cells at the periphery of pellets, more so in those formed without forskolin ([Figure 1](#fig1){ref-type="fig"}F). In support, the forskolin-treated cartilage pellets consisted mostly of SOX9^+^ chondrocytes, assessed as the proportion of GFP^+^ cells in cartilage generated from SOX9-GFP hiPSC-derived ectomesenchymal cells (mean % SOX9-GFP^+^ cells, 82.9 ± 11.7 \[SEM\]; [Figure 1](#fig1){ref-type="fig"}G). Thus, although forskolin and PTHrP(1--34) can be inhibitory for chondrogenesis from MSCs ([@bib16]), no sign of inhibition of chondrogenesis was observed in the hPSC-derived ectomesenchymal cells.

The Suppression of Hypertrophic Chondrocyte Gene Expression and Enhancement of Sulfated Glycosaminoglycan Production by Forskolin Are Not Affected by the Type of BMP Used {#sec2.2}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GDF5 and BMP7, members of the BMP family, are known to support chondrocyte hypertrophic differentiation only weakly ([@bib8], [@bib14], [@bib18]). However, under PTG or PT7 conditions, in which BMP4 in PTB is replaced with GDF5 or BMP7, respectively, the expression of *COL10A1* and *RUNX2* was induced during chondrogenesis to levels not significantly different from those under PTB (blue; [Figure 2](#fig2){ref-type="fig"}A). In contrast, forskolin treatment suppressed the expression of both genes (brown): e.g., expression of *COL10A1* was suppressed by 98% in PTB (from the relative expression of 0.25 to 0.0045) and 94% in PTG (from 0.26 to 0.015), while that of *COL2A1* and *SOX9* was not significantly affected. Changes in the expression of individual genes by forskolin treatment (+Fk) are summarized in [Figure 2](#fig2){ref-type="fig"}B, which shows the +Fk expression level normalized by the corresponding −Fk level (where −Fk = 1). Among hypertrophy genes, forskolin suppression of *COL10A1* expression was statistically significant in all BMP types tested. For the alkaline phosphatase gene (*ALPL*) and *RUNX2*, reproducible suppression was observed under PTB and PTG but not under PT7 conditions. Forskolin effects on *MMP13* expression were not significant under any of the BMP conditions tested. As expected, changes of the (immature) chondrocyte genes, *COL2A1* and *SOX9*, were weak and statistically insignificant. However, expression of *COL1A1* was significantly reduced by forskolin ([Figures 2](#fig2){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}A), suggesting that it may enhance hyaline chondrogenesis. Forskolin treatment also significantly reduced mRNA levels of *BMP4* in all BMP conditions.Figure 2Effect of Different BMPs on the Forskolin Suppression of Hypertrophic Chondrocyte Gene Expression and Forskolin Enhancement of Sulfated Glycosaminoglycan Production(A) Effect of replacement of BMP4 in PTB (PDGF + TGF-β+BMP4) with GDF5 (PTG) or BMP7 (PT7) on gene expression during chondrogenesis with (brown) or without (blue) forskolin (Fk). Mean relative expression levels from n = 3--5 (*COL2A1*), 3--6 (*SOX9* and *COL10A1*), and 3 (*RUNX2*) with SEM and p values. Additional data are provided in [Figure S3](#mmc1){ref-type="supplementary-material"}A.(B) Fold changes in expression by Fk addition. Mean values from n = 3--12 shown with SEM and p values. [Table S7](#mmc1){ref-type="supplementary-material"} shows all n and p values.(C) Quantitative comparison of the capacity of chondrocytes generated under PTB, PTG, and PT7 with (brown) or without (blue) Fk to produce sulfated glycosaminoglycan (sGAG). Top: Mean values of μg sGAG/μg DNA (n = 4--5) shown with SEM and p values. Bottom: Mean fold changes in the μg sGAG/μg DNA values by Fk treatment with SEM and p values (n = 4).

A high level of sGAG is a key indicator of healthy articular cartilage. Therefore, we investigated the effect of forskolin on sGAG accumulation in cartilage pellets. Under both PTB and PTG conditions, forskolin treatment resulted in a significant increase in the capacity of chondrocytes to produce sGAG ([Figure 2](#fig2){ref-type="fig"}C). The PT7 condition showed the same tendency but with only a weak statistical significance. Thus, forskolin supports hyaline cartilage formation by suppressing *COL1A1* expression and stimulating sGAG production from chondrocytes, consistent with a previous suggestion ([@bib30]), regardless of the type of BMPs used.

Exogenous cAMP Replaces Forskolin to Suppress *COL10A1* Expression during Chondrogenesis {#sec2.3}
----------------------------------------------------------------------------------------

Next, we set out to confirm that the suppressive effect of forskolin on *COL10A1* gene expression during chondrogenesis is dependent on the cAMP signaling pathways: i.e., one through PKA and/or another through the exchange protein directly activated by cAMP (EPAC) ([@bib5]). We tested the effects of the cAMP analogs *N*^*6*^-benzoyl cAMP (Bnz-cAMP) and 8-pCPT-2′-O-Me-cAMP-AM (CPT-cAMP), which preferentially bind and activate PKA and EPAC, respectively ([@bib11], [@bib41]). We also tested the effect of IBMX, an inhibitor of phosphodiesterase, the enzyme that degrades cAMP and cGMP. The PKA-activating Bnz-cAMP significantly inhibited *COL10A1* expression during chondrogenesis under PTB (+cAMP; [Figures 3](#fig3){ref-type="fig"}A and 3B) in a dose-dependent manner ([Figure S4](#mmc1){ref-type="supplementary-material"}A). IBMX at 0.5 mM also significantly reduced the *COL10A1* levels (+IBMX). These treatments had no significant effect on the level of *COL2A1* expression ([Figures 3](#fig3){ref-type="fig"}A and 3B). In contrast, the EPAC-activating CPT-cAMP reduced the *COL10A1* levels, albeit to a much smaller degree ([Figure S4](#mmc1){ref-type="supplementary-material"}A), and the cGMP antagonist Rp-8-Br-PET-cGMPS had no effect on *COL10A1* ([Figure S4](#mmc1){ref-type="supplementary-material"}B). These results suggest that suppression by forskolin of *COL10A1* expression during chondrogenesis involves the cAMP-PKA pathway.

Effect of Porcupine Inhibitor on the Forskolin-Dependent Decrease in *COL10A1* Expression during Chondrogenesis {#sec2.4}
---------------------------------------------------------------------------------------------------------------

Even in the presence of forskolin, *COL10A1* expression was induced*,* albeit slowly (only after day 20) and weakly (brown; [Figure 1](#fig1){ref-type="fig"}D), resulting in low but variable levels of background expression by day 28 of chondrogenesis (i.e., relative expression of *COL10A1* of between 0.0045 and 0.012; [Figure 2](#fig2){ref-type="fig"}A). We hypothesized that the hypertrophy-inducing canonical WNT signaling might contribute to such background expression. The weak (\<50%) inhibitory effect of Wnt-C59 ([Figure S2](#mmc1){ref-type="supplementary-material"}C) on *COL10A1* gene expression observed in the initial screening was reproducible ([Figure 3](#fig3){ref-type="fig"}B), consistent with [@bib37]. However, addition of Wnt-C59 with forskolin did not significantly enhance the inhibition of *COL10A1* expression due to forskolin alone ([Figure 3](#fig3){ref-type="fig"}B). Therefore, the residual expression of *COL10A1* in forskolin-treated cartilage pellets was probably not supported by endogenous WNT signaling.Figure 3Mechanistic Insight into the Effect of Forskolin on the Formation *In Vitro* of *COL2A1*^*+*^*COL10A1*^*lo*^ Cartilage from hESC-Derived Ectomesenchymal Cells(A) Effects of the cAMP analog, Bnz-cAMP, and PDE-inhibitor, IBMX, on *COL2A1* and *COL10A1* expression during chondrogenesis. Representative results of n = 3--4. Thin vertical line, SD of three technical repeats. cAMP, 80 μM Bnz-cAMP; IBMX, 0.5 mM. Additional data are provided in [Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B.(B) Mean fold changes in *COL2A1* and *COL10A1* expression by addition of a factor during chondrogenesis under PTB (PDGF + TGF-β + BMP4) are shown with SEM and p values. [Table S7](#mmc1){ref-type="supplementary-material"} shows all n and p values. Factors: cAMP, 100 μM Bnz-cAMP; IBMX, 0.5 mM; C59, 30 nM Wnt-C59. Changes by +Fk (forskolin) versus +C59: ^∗∗∗^p *=* 0.0031.(C and D) Quantitation of proliferating chondrocytes within cartilage pellets formed under PTB with or without Fk.(C) Left: Immunofluorescence image of Ki67 and COL2 staining of a PTBFk pellet. Right: Mean value of the % Ki67^+^ nuclei/total (DAPI^+^) nuclei of the COL2^+^ area from n = 4 with SEM with p value. The yellow arrow indicates the Ki67^+^ nucleus. Additional data are provided in [Figure S4](#mmc1){ref-type="supplementary-material"}C.(D) EdU incorporation. Left: EdU labeled chondrocytes formed from the SOX9-GFP hiPSC-derived ectomesenchymal cells under PTB and PTBFk were FACS analyzed. Representative image of n = 4. The pink dot plots represent cells gated with the pink gate (i.e., SOX9-GFP^+^ chondrocytes). Right: Mean % EdU^+^ cells within the SOX9-GFP^+^ cell population are shown with SEM and p value. Additional results are provided in [Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E.

Forskolin Promotes Accumulation of Proliferating Chondrocytes within Cartilage Pellets {#sec2.5}
--------------------------------------------------------------------------------------

Forskolin-treated cartilage may maintain *COL2A1*^+^*COL10A1*^*lo*^ hyaline chondrocytes either by blocking their hypertrophic differentiation or by supporting their proliferation and survival. PTHrP is known to maintain immature chondrocytes in a proliferative state in growth plate ([@bib1], [@bib24]). Since forskolin treatment caused a slight enlargement of cartilage pellets (1.31 ± 0.089 \[SEM\] fold increase in diameter, n = 7, p = 6.2E−04; [Figure 1](#fig1){ref-type="fig"}E), we tested whether forskolin mimicked the proliferative effect of PTHrP by immunostaining 30-day-old cartilage pellets with antibodies for Ki67, the protein marker for cell proliferation, and COL2. Forskolin treatment led to a significant increase in the proportion of chondrocytes expressing Ki67 in the cartilage pellets produced under PTB (indicated by the ratio of Ki67^+^ nuclei/DAPI^+^ nuclei in the COL2^+^ area; [Figure 3](#fig3){ref-type="fig"}C), although cartilage pellets formed under PTG and PT failed to show statistically significant differences ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Next, we conducted a 5-ethynyl-2′-deoxyuridine (EdU) incorporation study on day 26--28 cartilage pellets. The study demonstrated that addition of forskolin significantly increased the proportion of DNA-replicated chondrocytes (SOX9-GFP^+^EdU^+^ cells) within the cartilage pellets formed under PTB from SOX9-GFP hiPSC-derived ectomesenchymal cells ([Figures 3](#fig3){ref-type="fig"}D, [S4](#mmc1){ref-type="supplementary-material"}D, and S4E). These results support our hypothesis that forskolin increases the proportion of immature chondrocytes within the formed cartilage by stimulating chondrocyte proliferation.

Forskolin Suppresses *COL10A1* Expression without Affecting *COL2A1* Expression during Chondrogenesis in Different Cell Systems {#sec2.6}
-------------------------------------------------------------------------------------------------------------------------------

The SOX9-GFP hiPSC-derived ectomesenchymal cells that underwent chondrogenesis under PTB or PTG conditions also showed that the expression of *COL10A1* was selectively decreased by forskolin treatment ([Figure S3](#mmc1){ref-type="supplementary-material"}C). In addition, when chondrogenic paraxial mesoderm was derived from hESCs, expanded in a chemically defined medium (CDM) containing fibroblast growth factor (FGF) 2 and SB431542 and CHIR99021 (FSbC condition; [Figure 4](#fig4){ref-type="fig"}A) and subjected to pellet chondrogenesis culture under PTB, we observed a similar selective reduction in the *COL10A1* expression. The levels of *COL2A1* transcript were unchanged ([Figures 4](#fig4){ref-type="fig"}B and 4C).Figure 4Effects of Forskolin during Chondrogenesis from hESC-derived Paraxial Mesoderm and from Dedifferentiated Human Adult Nasal Chondrocytes(A) Graphical representation of the experimental procedure for developing chondrogenic paraxial mesoderm (PM). C, CHIR; N, Noggin; Fi, PD173074; P, PDGF; Sb, SB431542; T, TGFβ3; B, BMP4.(B and C) Mean relative expression levels of *COL2A1* and *COL10A1* in cartilage pellets formed under PTB and PTB with forskolin (PTBFk) (B), and mean fold changes in expression of *COL2A1* and *COL10A1* by Fk treatment (C) are shown with SEM and p value (n = 5).(D) Graphical representation of the experimental procedure for human nasal chondrocytes. SCM, serum-containing medium; FBS, fetal bovine serum.(E) *COL2A1* and *COL10A1* expression during chondrogenesis under T (green) and TB conditions with (TBFk, brown) or without (TB, blue) Fk. Square, cartilage from hESC-ectomesenchymal cells formed under PTB (NC); triangle, cartilage formed under PTBFk (NC + Fk). Thin vertical line, SD of three technical repeats. Results from two other patient samples are shown in [Figure S5](#mmc1){ref-type="supplementary-material"}A.(F) Immunofluorescence images of the cartilage pellets generated under T, TB, and TBFk conditions. Toluidine blue staining for sGAG is shown in [Figure S5](#mmc1){ref-type="supplementary-material"}B.

Nasal chondrocytes originate from cranial neural crest (i.e., ectomesenchymal cells). Therefore, adult nasal chondrocytes isolated from three patients were propagated (and inevitably dedifferentiated) and subjected to *in vitro* chondrogenesis as described ([@bib39]) ([Figures 4](#fig4){ref-type="fig"}D, 4E, and [S5](#mmc1){ref-type="supplementary-material"}A). The low levels of *COL2A1* and *COL10A1* mRNA detected on days 6--9 of differentiation declined to a near undetectable level (relative expression level of 0.001) by day 28 in the presence of TGFβ3 alone (T, green). However, the addition of BMP4 on day 10 stimulated *COL2A1* expression and to a much lesser degree, *COL10A1* expression (TB, blue). The addition of forskolin (TBFk, brown) on day 12 selectively knocked down the BMP4-supported *COL10A1* expression without affecting the BMP4-enhanced *COL2A1* expression. Furthermore, immunohistological analyses supported the finding that in nasal cartilage pellets, the accumulation of COL2 ([Figure 4](#fig4){ref-type="fig"}F) and sGAG ([Figure S5](#mmc1){ref-type="supplementary-material"}B) was dependent on BMP4 and independent of forskolin.

Thus, chondrogenesis from human neural-crest-derived ectomesenchymal cells, human paraxial mesoderm-derived chondroprogenitors, and dedifferentiated adult human nasal chondrocytes is sensitive to forskolin treatment, which leads to the suppression of the BMP-stimulated commitment of the developed chondrocytes to hypertrophic differentiation without affecting the enhancement of chondrogenesis by BMP.

Forskolin Treatment Maintains the Expression of Genes Representing "Proliferative" and "Primitive" Stages of Chondrocytes {#sec2.7}
-------------------------------------------------------------------------------------------------------------------------

To elucidate the type of cartilage that forskolin forms preferentially and the potential molecular mechanisms involved in the process, we performed genome-wide, comparative transcriptome analyses on the cartilage pellets formed from three to four independent pellet cultures of ectomesenchymal cells under PTB conditions with or without forskolin treatment. RNAs were isolated on day 26--28 and mRNA-sequencing analyses were performed. The principal component analysis and heatmap demonstrated that forskolin-treated cartilage pellets were distinct from forskolin-untreated cartilage pellets ([Figures 5](#fig5){ref-type="fig"}A and 5B). Gene ontology (GO) analysis on differentially expressed genes (DEGs, genes showing more than a 2-fold difference in the expression level between forskolin-treated and untreated pellets; [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}) indicated that forskolin treatment during chondrogenesis would likely enhance "(nuclear) chromosome segregation" in the cells, suggesting the enhancement of the cell division cycle of chondrocytes ([Figure 5](#fig5){ref-type="fig"}C, [Table S1](#mmc1){ref-type="supplementary-material"}). In support, the forskolin-induced gene set contained various cell-cycle regulator genes, including *CCNA2/B2*, *CDK1/18*, and *CDC45* ([@bib38]), and DNA replication genes such as *MCM10*, *ORC1*, and *CDT1* ([@bib43]) ([Figure 5](#fig5){ref-type="fig"}E, [Table S3](#mmc1){ref-type="supplementary-material"}). Consistently, the forskolin-suppressed gene set included the p21^CIP1^ cell-cycle inhibitor gene, *CDKN1A* ([Figure 5](#fig5){ref-type="fig"}F, [Table S4](#mmc1){ref-type="supplementary-material"}).Figure 5Comparative Transcriptome Analysis of Cartilage Pellets Using the RNA-seq Technology(A) Principal component analysis of the expression pattern of protein-coding genes between PTB (PDGF + TGF-β + BMP4, red) and PTBFk (PTB + forskolin, blue) cartilage pellets.(B) Heatmap of the differentially expressed genes (DEG).(C and D) Gene ontology (GO) analysis. GO categories for forskolin (Fk)-induced genes (brown bars) and Fk-suppressive genes (blue bars). (C) Top GO categories (p \< 1.0E−17) from [Table S1](#mmc1){ref-type="supplementary-material"}. (D) Skeletogenesis-related GO terms (p \< 1.0E−04) from [Table S2](#mmc1){ref-type="supplementary-material"}.(E and F) Selected lists of Fk-induced genes (E) from [Table S3](#mmc1){ref-type="supplementary-material"} and Fk-suppressive genes (F) from [Table S4](#mmc1){ref-type="supplementary-material"}.

Furthermore, GO analysis suggested that forskolin treatment during chondrogenesis would promote "cartilage development" and "connective tissue development," but suppress "ossification," "osteoblast differentiation," "biomineral tissue development," "bone development," and the "BMP signaling pathway" ([Figure 5](#fig5){ref-type="fig"}D, [Table S2](#mmc1){ref-type="supplementary-material"}). In support, the forskolin-induced gene set contained genes associated with chondrogenesis such as *RUNX1* ([@bib57]), *PBX3* ([@bib7]), and *TGFBR3*, genes involved in nasal cartilage specification such as *ALX4* ([@bib3]) and *SIX2* ([@bib19]), the mineralization inhibitor gene, *UCMA* ([@bib47]), and BMP inhibitor genes such as *GREM1* ([@bib28]) and *CHRDL2* ([@bib34]) ([Figure 5](#fig5){ref-type="fig"}E, [Table S3](#mmc1){ref-type="supplementary-material"}). In contrast, the forskolin-suppressed gene set included inducers of chondrocyte hypertrophy such as *RUNX2* ([@bib13]), *Osterix/SP7* ([@bib32]), and *FOXA2* ([@bib22]) as well as *IHH* ([@bib44]), indicator genes of chondrocyte hypertrophy such as *COL10A1* and A*LPL*, genes associated with (chondrocyte) mineralization and bone formation such as *IBSP*, *SPP1*, *MEPE* ([@bib4]), and *IRX5* ([@bib2]), and those associated with BMP and its signaling targets such as *BMP2* and *SMPD3* ([@bib23]) ([Figure 5](#fig5){ref-type="fig"}F, [Table S4](#mmc1){ref-type="supplementary-material"}). Real-time RT-PCR of some of these genes has confirmed the differential expression ([Figure S3](#mmc1){ref-type="supplementary-material"}B).

These results are strikingly consistent with our previous observations that forskolin treatment keeps the chondrocytes in an immature state by suppressing their commitment to hypertrophic differentiation, probably through enhancement of chondrocyte proliferation ([Figures 3](#fig3){ref-type="fig"}C and 3D).

Forskolin-Treated Cartilage Pellets Are Better Maintained in an Unmineralized State *In Vivo* than Untreated Pellets {#sec2.8}
--------------------------------------------------------------------------------------------------------------------

Based on a prediction from the report of [@bib44], we examined whether the suppression by forskolin of the commitment of chondrocytes to hypertrophic differentiation in cartilage developed *in vitro* would lead to suppression of post-transplantational mineralization of the cartilage. We subjected ectomesenchymal cells to pellet culture for 28--33 days under PTB, PTG, and PT7 conditions with or without forskolin treatment. The resulting pellets were transplanted subcutaneously into NSG mice, harvested 8 weeks later ([Figure 6](#fig6){ref-type="fig"}A), and analyzed immunohistochemically. Metachromatic staining of TB, which indicates the presence of sGAG, would confirm the presence of active chondrocytes, whereas black von Kossa staining (VK), a sign of calcium accumulation would indicate chondrocyte mineralization and bone formation. [Figures S6](#mmc1){ref-type="supplementary-material"}A--S6C classify the types of cartilage pellets recovered. Analyses were focused on the TB^+^VK^lo^ full-cartilage pellet that maintained cartilaginous matrix (sGAG \[TB^+^\] and COL2) with minimal signs of mineralization (VK^lo^) and COL10 expression, and the TB^−^VK^+^ bony pellets that lost sGAG (TB^−^) and were fully mineralized (VK^+^) but still contained COL10^+^ hypertrophic chondrocytes ([Figures 6](#fig6){ref-type="fig"}B and 6C).Figure 6*In Vivo* Stability of Cartilage Pellets Formed from hESC-Derived Ectomesenchymal Cells in the Presence of Forskolin(A and B) Graphical representation of the experimental procedure and examples of recovered cartilage: near-intact toluidine blue (TB)^+^, von Kossa (VK)^lo^ full cartilage, and completely mineralized TB^−^VK^+^ bony pellet (ppt). The criteria for the different types of cartilage pellets are summarized in [Figures S6](#mmc1){ref-type="supplementary-material"}A--S6C.(C) Immunofluorescence study of the TB^+^VK^lo^ full cartilage (blue) and the TB^−^VK^+^ bony ppt (red). See [Figure S6](#mmc1){ref-type="supplementary-material"}D.(D) Mean frequencies (freq.) of full cartilage, partial cartilage, and bony ppt recovery from transplantation experiments using cartilage pellets (ppts) generated under PTB (PDGF + TGF-β + BMP4), PTB + forskolin (PTBFk), PTG (PDGF + TGF-β + GDF5), PTGFk, PT7 (PDGF + TGF-β + BMP7), or PT7Fk conditions. Mean frequencies of absorption are also shown. [Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B shows graphical representations with statistics.(E) Mean frequencies of full cartilage, partial cartilage, and bony ppt recovery from all three BMP conditions tested (n = 3) with or without Fk treatment are presented with SEM and p values. Cumulative data and analyses are presented in [Figures S7](#mmc1){ref-type="supplementary-material"}C--S7E.

As shown in [Figure 6](#fig6){ref-type="fig"}D, the addition of forskolin to PTB-based pellet culture increased the recovery of TB^+^VK^lo^ full-cartilage pellets from 0% to 13.3% of total recovered pellets (n \[independent transplantation\] = 9--10, p = 0.18; not statistically significant; [Figure S7](#mmc1){ref-type="supplementary-material"}A), and led to a concomitant decrease in the frequency of TB^−^VK^+^ bony pellets from 75.8% to 48.3% (p = 0.050; [Figure S7](#mmc1){ref-type="supplementary-material"}A). Similarly, forskolin addition to PTG culture significantly improved the maintenance *in vivo* of TB^+^VK^lo^ cartilage from 0% to 25.0% (n = 7--8, p = 0.023; [Figure S7](#mmc1){ref-type="supplementary-material"}A). Forskolin addition to PT7 culture also improved TB^+^VK^lo^ cartilage maintenance from 0% to 12.5% (n = 5--6, p = 0.24, not statistically significant; [Figure S7](#mmc1){ref-type="supplementary-material"}A). Interestingly, however, the recoveries of TB^+^VK^lo^ full cartilage (increased by forskolin, p = 0.014) and TB^−^VK^+^ bony pellet (decreased by forskolin, p = 0.089) were surprisingly consistent, regardless of the type of BMP used to promote cartilage pellet formation ([Figure 6](#fig6){ref-type="fig"}E). The analysis based on cumulative data led to similar results ([Figures S7](#mmc1){ref-type="supplementary-material"}C--S7E).

In conclusion, while forskolin treatment did not completely inhibit the BMP-promoted commitment of chondrocytes to hypertrophic differentiation during *in vitro* chondrogenesis from ectomesenchymal cells, it significantly and specifically counteracted such effects of BMP (but not BMP-facilitated hyaline chondrogenesis), and improved the maintenance of cartilage at an unmineralized or less mineralized state *in vivo* without loss of the capacity to produce cartilage matrix.

Discussion {#sec3}
==========

We have demonstrated that the commitment of chondrocytes in cartilage pellets developed *in vitro* from the hPSC-derived chondroprogenitors to hypertrophic differentiation can be inhibited by forskolin treatment, and such *in vitro* treatment can have a lasting effect on the fate of the resulting chondrocytes; namely inhibition of further maturation, mineralization, and bone formation, even after transplantation ([Figure 7](#fig7){ref-type="fig"}). Furthermore, forskolin achieved this effect, at least in part, by maintaining chondrocytes in a primitive, proliferative state.Figure 7Schematic Representation of the Role of *In Vitro* Forskolin Treatment on the Pre- and Post-transplantational Fate of Cartilage Developed from hPSCs

We used forskolin as a PTHrP mimic. Attempts to use PTHrP or PTHrP(1--34) peptide to suppress hypertrophic differentiation of chondrocytes developed *in vitro* from MSCs have thus far yielded contradictory results. In earlier studies, PTHrP enhanced COL2 expression and weakly suppresses COL10 expression ([@bib25]). PTHrP in chondrocyte conditioned medium also suppressed COL10 expression ([@bib15]). However, in later studies, PTHrP was inhibitory for chondrogenesis and suppressed the expression of both *COL2A1* and *COL10A1* ([@bib53]), although intermittent administration of PTHrP(1--34) was found to alleviate the situation to some extent ([@bib16]). Chondrogenesis from adult MSCs in the presence of TGF-β induced the expression of *COL2A1* and *COL10A1* simultaneously ([@bib16], [@bib53]). In contrast, chondrogenesis from the hPSC-derived chondroprogenitors showed sequential induction of *COL2A1* then *COL10A1*, so resembling the maturation process of chondrocytes in the growth plate. It is therefore tempting to speculate that our success in the use of forskolin to reproducibly suppress signs of chondrocyte hypertrophic differentiation *in vitro* without affecting hyaline chondrogenesis may be attributed to the stage-specific administration of forskolin (i.e., after *COL2A1* but before *COL10A1* induction) used in our hPSC-derived cell system.

BMPs are known to facilitate the hypertrophic differentiation of chondrocytes *in vitro* at different efficiencies dependent on the BMP used; e.g., GDF5 and BMP7 are not very effective or sometimes inhibitory ([@bib8], [@bib14], [@bib18]). In fact, BMP7 weakly induced *COL10A1* and *ALPL* expression, and GDF5 induced it to levels between those achieved with BMP7 and BMP4 ([Figures 2](#fig2){ref-type="fig"} and [S3](#mmc1){ref-type="supplementary-material"}A). These differences, however, did not reflect the *in vivo* stability of developed cartilage pellets, so that no cartilage remained as TB^+^VK^lo^ full cartilage after 8 weeks regardless of BMP ([Figures 6](#fig6){ref-type="fig"}D and [S7](#mmc1){ref-type="supplementary-material"}). In addition, conditions without exogenous BMPs (PT condition) have thus far showed no significant improvements ([Figure S7](#mmc1){ref-type="supplementary-material"}), contrary to the expectation from the previous studies using mesodermal progenitors ([@bib12]). Therefore, the use of no BMP, or a particular type of BMP, could not substitute effectively for forskolin in the promotion of long-lasting cartilage formation from ectomesenchymal cells.

We performed comparative bioinformatics analyses with [@bib54] human embryonic chondrocyte databases (GEO: [GSE51812](ncbi-geo:GSE51812){#interref0010}), but found no significant indications of forskolin-promotion of articular chondrocyte formation in our cultures ([Tables S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}), similar to the effects of GREM1, FRZB, and DKK1 on the MSC chondrogenesis ([@bib28]). However, the GO analysis implicated forskolin suppression of the "BMP signaling pathway" among the most probable biological mechanisms of forskolin ([Figure 5](#fig5){ref-type="fig"}D). In fact, we observed that forskolin induced BMP inhibitor gene expression and suppressed BMP signaling gene expression ([Figures 2](#fig2){ref-type="fig"}B, 5E, 5F, and [S3](#mmc1){ref-type="supplementary-material"}B, [Tables S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}). Since exogenous forskolin and BMPs were not present *in vivo*, suppression of the intrinsic capacity of cartilage pellets to activate BMP signaling may contribute to the improved maintenance of transplanted cartilage pellets at an unmineralized or less mineralized state for 8 weeks.

Significant fractions of the forskolin-treated cartilage pellets recovered from ectopic transplantation were mineralized ([Figures 6](#fig6){ref-type="fig"}, [S6](#mmc1){ref-type="supplementary-material"}, and [S7](#mmc1){ref-type="supplementary-material"}), possibly due in part to preferential absorption of unmineralized cartilage pellets generated *in vitro* with forskolin. We have noted that forskolin treatment resulted in increased pellet loss, although only the PTB condition gave statistically significant differences: from 10.4% (PTB) to 36.5% (PTBFk) (p = 0.084; [Figure S7](#mmc1){ref-type="supplementary-material"}B). However, the mean increased rate of loss of forskolin-treated pellets was consistent, regardless of the type of BMP used for cartilage pellet formation (p = 0.0010; [Figure 6](#fig6){ref-type="fig"}E). Furthermore, the results may be due to the background expression of hypertrophy-inducer genes such as *RUNX2*, *SP7*, *BMP2*, and *BMP4*, which was not completely suppressed by forskolin. These gene products may be upregulated and become functional after transplantation to promote mineralized cartilage formation. Additional blocking of WNT signaling by a porcupine inhibitor did not significantly improve the *in vitro* effect ([Figure 3](#fig3){ref-type="fig"}B) and *in vivo* consequence (data not shown) of forskolin treatment. Therefore, manipulation of other mechanisms may be needed.

Thus, one of the advantages of the hPSC-derived chondroprogenitor cell system for generating tissue-engineered cartilage is that the post-transplantational fate of developed chondrocytes can be more robustly controlled at a pre-transplantational stage (i.e., *in vitro*), compared with the adult MSC systems reported ([@bib15], [@bib37], [@bib53]). Mechanistic studies to understand how these processes work are necessary, not only to improve the efficacy of hPSC-based cartilage regenerative therapy but also to apply the mechanism to the more clinically relevant adult stem cells for better therapeutic outcomes.

Experimental Procedures {#sec4}
=======================

Human Pluripotent Stem Cell Culture {#sec4.1}
-----------------------------------

H9 (WA09) hESCs from WiCell were maintained on mouse embryonic fibroblast feeder cells. CY2-SOX9-2A-ZsGreen-2A-Puro (SOX9-GFP) hiPSCs from NIH were maintained in E8 medium as described ([@bib50]). Human PSC experiments were under the regulation of SCRO for the University of Texas Health Science Center at Houston (UTHealth).

Generation and Expansion of Ectomesenchymal Cells from hPSCs through Neural Crest Specification {#sec4.2}
-----------------------------------------------------------------------------------------------

Human ESCs and iPSCs were differentiated, and the neural crest-like progeny were purified by fluorescence-activated cell sorting (FACS) and expanded as described ([@bib50]).

Generation and Expansion of Paraxial Mesoderm from hPSCs {#sec4.3}
--------------------------------------------------------

Human ESCs were differentiated using the improved embryoid-body-forming culture method ([@bib50]). Paraxial mesoderm cells were isolated by FACS as described ([@bib49]), and were then expanded in CDM ([@bib50]) supplemented with FGF2, PDGF, SB431542, and CHIR99021 (FPSbC medium). At passage 2, PDGF was removed (FSbC).

Expansion of Human Adult Nasal Chondrocytes {#sec4.4}
-------------------------------------------

Human adult nasal chondrocytes from one female (11F) and two male patients (12M, 13M) were independently isolated and expanded to passage 3 as described ([@bib9]).

Scaffold-free Cartilage Formation: Pellet Culture {#sec4.5}
-------------------------------------------------

Chondrogenesis was induced by pellet culture as described ([@bib50]). Chondrogenesis from human nasal chondrocytes was performed as described ([@bib39]).

Isolation of Chondrocytes from Cartilage Pellets {#sec4.6}
------------------------------------------------

A cartilage pellet was treated with 4 mg/mL collagenase in the pellet culture medium ([@bib50]) at 37°C for 3 hr and dissociated to single cells by repetitive pipetting.

Isolation and Quantification of DNA, RNA, and sGAG from Cartilage {#sec4.7}
-----------------------------------------------------------------

DNAs and sGAGs from cartilage pellets were isolated, quantified, and analyzed as described ([@bib50]).

EdU Incorporation Assay {#sec4.8}
-----------------------

Cartilage pellets were labeled with EdU for 21--25 hr. Then chondrocytes were isolated and processed using the Click-iT plus EdU Alexa Fluor 647 Kit (Invitrogen) and analyzed by FACS.

Gene Expression Profiling {#sec4.9}
-------------------------

Real-time RT-PCR experiments were performed as described ([@bib50]). The results are presented as mean relative expression levels (against *EEF1A1*) with SEM shown by thin error lines. The change in expression was a relative expression of a gene in treated (+) pellets normalized against that in the corresponding untreated (−) pellets. RNA sequencing (RNA-seq) was performed on an Illumina Nextseq500. Sequenced reads (GEO: GSE116173) were mapped against the human reference genome (hg19). Expression levels were calculated as normalized gene counts from DESeq2 ([Figure 5](#fig5){ref-type="fig"}, [Tables S1--S4](#mmc1){ref-type="supplementary-material"}).

Subcutaneous Transplantation of Cartilage Particles {#sec4.10}
---------------------------------------------------

The subcutaneous transplantation was performed as described ([@bib50]), under the regulation of IACUC for UTHealth.

Immunohistological Staining {#sec4.11}
---------------------------

The cartilage pellets made *in vitro* were fixed with Zn-formalin, paraffin embedded, sectioned, and subjected to immunofluorescence detection of COL1, COL2, and Ki67.

Statistical Analysis {#sec4.12}
--------------------

Statistical differences between groups were determined by Student\'s t test (2 categories) or one-way ANOVA(\>2 categories) followed by the Student-Newman-Keuls multiple comparisons. n is the number of independent experiments. p \< 0.2 values are shown as numbers in the bar graphs. Mean values that give p ≥ 0.1 from the +/− treatment comparisons are shown in light-colored bars.

Note Added in Proof {#sec4.13}
-------------------

During revision of this manuscript, [@bib55] published a report demonstrating that inhibition of κ-opioid receptor/cAMP signaling accelerated the degeneration of injured articular cartilage.
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